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Abstract 
Objective  
To refine and validate a model for predicting the risk of gastro-intestinal (GI) cancer in iron deficiency 
anaemia (IDA), and to develop an App to facilitate use in clinical practice.  
Design 
Three elements - (1) Analysis of a dataset of 2390 cases of IDA to validate the predictive value of age, 
sex, blood haemoglobin concentration (Hb), mean cell volume (MCV) and iron studies on the 
probability of underlying GI cancer (2) A pilot study of the benefit of adding faecal immunochemical 
testing (FIT) into the model (3) Development of an App based on the model. 
 
Results  
Age, sex and Hb were all strong, independent predictors of the risk of GI cancer, with ORs (95% CI) of 
1.05 per year (1.03 – 1.07, P<0.00001), 2.86 for males (2.03 – 4.06, P<0.00001), and 1.03 for each g/l 
reduction in Hb (1.01 – 1.04, P<0.0001) respectively. An association with MCV was also revealed, with 
an OR of 1.03 for each fl reduction (1.01 – 1.05, P<0.02). The model was confirmed to be robust by 
an internal validation exercise. In the pilot study of high-risk cases, FIT was also predictive of GI cancer 
(OR = 6.6, 95% CI 1.6 - 51.8), but the sensitivity was low at 23.5% (95% CI 6.8 – 49.9%). An App based 
on the model was developed. 
Conclusion 
This predictive model may help rationalise the use of investigational resources in IDA, by fast-tracking 
high-risk cases and, with appropriate safeguards, avoiding invasive investigation altogether in those 
at ultra-low predicted risk. 
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Summary Box 
 
 
 
 
 
 
 
  
1. What is already known about this subject? 
• GI cancer is the cause of IDA in 8 – 10% of adult males and post-menopausal females 
• The risk of GI cancer in IDA is influenced by age, sex and Hb 
• Faecal immunochemical testing in IDA may be of value in identifying underlying GI cancer 
2. What are the new findings? 
• Age, sex, and Hb are confirmed as strong predictors of the risk of GI cancer in IDA 
• MCV is an additional independent predictor of the risk 
• In combination, these four predictors can identify 10% of the referred IDA population who are 
at ultra-low risk of GI cancer. 
• FIT is predictive of GI cancer risk in high-risk individuals with IDA, though the sensitivity is low 
• An App can facilitate the use of the model in a clinical setting 
 
3. How might it impact on clinical practice in the foreseeable future? 
• The predictive model may allow the use of investigational resources to be rationalised in IDA, 
by fast-tracking high-risk cases and, with appropriate safeguards, avoiding invasive 
investigation altogether in those at ultra-low predicted risk 
• The App is intended to facilitate the use of this model in a clinical setting 
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Introduction 
Iron deficiency anaemia (IDA) is a common clinical problem, with an overall incidence in western 
populations approaching two cases per 1,000 pa, and a considerably higher age-specific incidence in 
those over the age of 70 1 2. More than a quarter of males and post-menopausal females with IDA 
have significant underlying gastro-intestinal (GI) pathology, and malignancy is by far the most 
important cause, found in 8 – 10% of cases 3-5. IDA is an important indicator of GI cancer, particularly 
cancer of the right colon, as it often occurs before any other clinical pointer to the diagnosis 6. 
The IDA clinic at Poole Hospital is the point of referral for the many patients with IDA who have 
minimal or no symptoms to indicate the nature or location of the underlying cause of iron deficiency, 
and for whom further assessment is felt to be warranted. Basic patient data has been collected since 
inception for the purpose of clinical care, audit and service evaluation. The referral rate to the IDA 
clinic now exceeds 400 new patients per annum 2 7. 
In view of the possibility of underlying GI cancer, it is current standard practice to advise urgent 
investigation of at-risk subjects with IDA - which in the first instance generally involves gastroscopy 
and colonoscopy / colonography to examine the upper and lower GI tract respectively 8. These 
investigations are however expensive and labour-intensive, and not entirely without risk of problems 
and complications, particularly in those with significant co-morbidities. Furthermore, over 80% of 
investigations for IDA will not reveal significant pathology.  
As individuals with IDA are likely to vary in their individual likelihood of malignancy, a simple but 
reliable pre-investigation predictor of GI cancer risk would help considerably with patient counselling. 
Risk stratification could also rationalise the use of resources, with prioritisation of high-risk subjects 
for fast-track investigation, and perhaps avoidance of invasive investigation altogether in particularly 
low-risk individuals. 
Previous work by our group and others 9 10 has demonstrated that three simple and objective clinical 
variables - age, sex and blood haemoglobin concentration - appear to be independent predictors of 
underlying GI cancer in IDA. In the IDIOM (Iron Deficiency as an Indicator Of Malignancy) study of an 
IDA cohort of 720, the combination of these variables was used to derive a score corresponding to 
the percentage probability of underlying GI malignancy - which ranged from less than 2% in low-risk 
subgroups to more than 20% in high-risk subgroups 10. These studies 9 10 do however have the 
shortcomings that both were retrospective in design and lacked an a priori hypothesis, simply 
because there was insufficient evidence on which to base such a hypothesis. 
The aims of the study reported here were threefold. First, to provide prospective validation of the 
independent variables identified in the original IDIOM study as predictors of underlying GI cancer, by 
analysing a much larger IDA cohort, and to determine whether mean cell volume and iron studies 
(transferrin saturation / serum ferritin) might prove to be additional predictors of risk. Second, to 
undertake a pilot study to explore whether faecal immunochemical testing for small quantities of 
human haemoglobin in faecal specimens can improve risk stratification still further. The rationale for 
this hypothesis is that chronic low-grade blood loss from the tumour bed is assumed to be the major 
 5 
factor contributing to the development of IDA in subjects with GI cancer. Third, to develop an App 
for use in the clinical setting to provide an instant assessment of GI cancer risk following the input of 
simple clinical data.  
Method 
Validation study 
The first part of the study involved a detailed assessment of clinical data for subjects referred for  
assessment in the Poole IDA clinic with confirmed iron deficiency by standard laboratory criteria 
(transferrin saturation <15% and / or serum ferritin concentration less than the lower limit of the 
reference interval for the laboratory at the time) who were assessed between 2004 and 2018 
inclusive 2, incorporating some cases included in a previous report 10. Cases presenting in 2004 – 2016 
formed the training dataset, whilst those presenting in 2017 – 2018 provided the validation dataset. 
Developing the model using the training dataset was carried out in 2018, before receiving the 
validation dataset. 
The final datasets included age at presentation and sex, blood test results (Hb, MCV and iron studies) 
and the diagnostic findings on standard investigation of the upper and lower GI tract. Data sets were 
complete for age, sex, Hb, MCV and presence / absence of GI malignancy. As results were available 
for both transferrin saturation and serum ferritin in only 36.8% of the study population, iron 
deficiency was analysed as a dichotomous variable, being “severe” (arbitrarily defined as a transferrin 
saturation <10% and /or a serum ferritin <10 µg/l) or “non-severe” (criteria for severe deficiency not 
met).  
Anonymised data were analysed to assess whether the five clinical parameters could usefully predict 
the likelihood of GI malignancy on subsequent investigation. Data preparation involved cleaning the 
data by checking and correcting any unusual values, removing duplicate entries, and retaining only 
the first record for any patient referred more than once to the IDA clinic. A training dataset was used 
to derive the prediction model, which was then tested on a validation dataset. As this was a 
secondary analysis of anonymised data, formal Research Ethics approval was not required for this 
element of the study. 
Logistic regression models were run for each of the predictors separately, with GI cancer as the 
outcome. When any significant association was found between a predictor and GI malignancy 
(p<0.05), this predictor was added to a multivariable logistic regression model. Smoothed scatter 
plot, Cook’s distance and standardised residual errors, variance inflation factor, Akaike information 
criterion (AIC), Anova chi square test, Pseudo R squared and the Hosmer-Lemeshow test were used 
to check the validity of the fitted logistic regression model and the goodness of fit 11. 
To assess the performance of the fitted model derived from the training dataset, we examined how 
well it predicted GI cancer in the validation dataset. Cut-off metrics 12 13 were used to assess 
performance, because traditional evaluations such as overall accuracy were not appropriate 14 in 
view of the small percentage of participants with GI malignancy in the study. A classification cut-
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off probability (decision threshold) was identified using the training data, in which a value above that 
cut-off indicates the presence, and a value below the absence of GI cancer. The prediction model was 
then tested on the validation dataset using this cut-off. Three optimal prediction cut-offs were 
selected :  
1. Cut-off 1 - the highest cut-off at which the negative predictive value (NPV) remains 100%. NPV is 
the number of negative cases that were correctly classified divided by the total number of negative 
cases predicted 15. This cut-off identifies subjects who are at ultra-low risk of GI cancer. 
2. Cut-off 2 - at which geometric mean (G mean) of sensitivity and specificity is highest 16. G mean is 
calculated from the formula: �(sensitivity ∗ specificity) 17 18 
3. Cut-off 3 – the lowest cut-off at which the positive predictive value (PPV) remains in the upper 
quartile (ie the point below which 75% of PPVs lie). PPV is the number of positive cases that were 
correctly classified divided by the total number of positive cases predicted 15. This cut-off identifies 
patients who are at high risk of GI cancer. 
Receiver operating characteristic (ROC) was used to compare and visualise the effectiveness of the 
predictive model at separating positive and negative classes according to each cut-off 19. 
 
 
FIT pilot study 
A pilot study to explore the potential role of FIT - IDIOM-3 (ISRCTN No 18342140) - was undertaken 
with Research Ethics approval (IRAS No 201759). In brief, 80 subjects were prospectively identified 
who fulfilled all of the following criteria : (1) confirmed IDA, (2) high GI cancer risk based on age and 
Hb (70 years or over and < 100 g/l respectively) 10, (3) listed for investigation with gastroscopy and 
colonoscopy / colonography. Each was invited to provide a faecal sample for FIT prior to invasive 
investigation, using the Hema-screen SPECIFIC kit (Alpha Laboratories, Eastleigh, UK) - the 
manufacturer’s published analytical detection limit for this test is 50 μg Hb/g faeces 20. FIT analysis 
was undertaken without knowledge of the outcome of GI investigation.  
 
App development 
To simplify utilisation of the prediction model in clinical settings, a web-based Application was 
developed. R (version 3.6.1), RStudio (version 1.2.5001), R Shiny and DT packages were used to run 
the statistical analysis and to build the App.   
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Results 
Validation study 
Over 2800 subjects with iron deficiency were seen in the IDA clinic during the study period. Excluding 
those in whom investigations were not completed due to patient preference, frailty or concurrent 
illness, and those whose records were incomplete, left 2390 subjects for detailed analysis. For the 
validation study, there were 1879 in the training dataset and 511 in the validation dataset.  
The total study group comprised 1528 females and 862 males (a sex ratio of 1.8), with a median age 
of 71 years (inter-quartile range : 59-79 years) and mean (SD) values for Hb and MCV of 103 (17.4) 
g/l and 80.0 (9.1) fl respectively. The arbitrary criteria for severe iron deficiency were met by 57% of 
the study population. GI carcinoma was identified in 200 individuals in the study group, giving an 
overall prevalence of 8.4%. Of those 172 (86%) were in the lower GI tract, and of those 140 (81%) 
were in the right colon.  
Comparison of the training and validation datasets revealed marginally higher values for mean Hb 
(102 v 106 g/l, P <0.001) and mean MCV (79.4 v 82.2 fl, P<0.001) in the latter. This is consistent with 
changes in the characteristics of our IDA population over time reported elsewhere 2. There were 
otherwise no significant differences between the training and validation datasets for any of the key 
variables.  
Analysis of the training dataset confirmed that age, sex and Hb were all strong, independent 
predictors of the risk of GI cancer. MCV was also predictive though there was greater variability, 
resulting in a wider confidence interval. There was no significant relationship with the results of iron 
studies. The final multiple binary logistic regression model was therefore constructed according to 
the formula: ln(GI_cancer) ~ β0 + β1age + β2sex + β3Hb + β4MCV. Statistical assessment of validity and 
goodness of fit of the logistic regression model based on the criteria outlined in the Method section 
was satisfactory. 
The odds ratios (95% CI, P value) for the four predictive variables were as follows :  
• Age - 1.05 per year (1.03 – 1.07, P<0.00001) 
• Sex - 2.86 for males (2.03 – 4.06, P<0.00001) 
• Hb - 1.03 for each g/l reduction (1.01 – 1.04, P<0.0001) 
• MCV - 1.03 for each fl reduction (1.01 – 1.05, P<0.02) 
The ROC curve for the training dataset shows the true positive rate on Y axis (sensitivity) and false 
positive rate on X axis (1-specificity), along with the three optimal cut-offs described in the Method 
section (Figure 1). Using the regression model to calculate predicted GI malignancy risk, cut-off 1 (risk 
1.5%) was able to stratify about 10% of both cohorts into an ultra-low risk sub-group. Cut-off 2 (risk  
7.4%) maximised G mean in the training dataset (69.2% ; 95% CI 21.8 – 219.9%) and gave a 
comparable value in the validation dataset (73.2% ; 95% CI 27.4 – 195.6%), with closely overlapping 
confidence intervals and similar values for sensitivity and specificity. Cut-off 3 (risk 11.1%) stratified 
about 25% of both cohorts into a high risk sub-group. These results (summarised in Table 1) 
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demonstrate that the model is robust in predicting the risk of underlying GI cancer in a new IDA 
dataset collected in a different time period. 
 
Figure 1 Receiver operating characteristic (ROC) curve for the training dataset, showing the three 
optimal cut-off points defined in the text : cut-off 1 = 1.5%, cut-off 2 = 7.4%, cut-off 3= 11.1%. AUC = area 
under curve. 
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Table 1 Characteristics of the three optimal cut-off points for predicted probability of GI cancer, as 
applied to the training and validation datasets. NPV = negative predictive value, G mean = geometric 
mean, PPV = positive predictive value 
 
Threshold Criterion Training Dataset (%) Validation Dataset (%) 
Optimal cut-off 
1 
(1.5%) 
NPV = 100% 
Sensitivity (95% CI) 100.0 (97.7-100.0) 100.0 (91.8-100.0) 
NPV (95% CI)  100.0 (98.0-100.0) 100.0 (95.1-100.0) 
Optimal cut-off 
2 
(7.4%) 
G mean 
Sensitivity (95% CI) 75.8 (68.3-82.3) 79.1 (63.9-89.9) 
Specificity (95% CI) 63.2 (60.9-65.5) 67.7 (63.3-71.9) 
Optimal cut-off 
3 
(11.1%) 
PPV in highest 
quartile 
Sensitivity (95% CI) 56.1 (47.9-63.9) 60.5 (44.4-75.0) 
PPV (95% CI) 18.6 (15.2-22.4) 23.9 (16.2-32.9) 
 
 
The striking effect of combining the predictive variables on predicted risk is displayed in heat-map 
format in Figure 2. This demonstrates the high risk in all older males with IDA regardless of 
haematology findings, and the extremely low risk in younger females with marginal anaemia and a 
normal MCV. None of the individuals with a risk predicted by the model of less than 1.5% proved to 
have GI cancer on investigation - accounting for 10% of the whole cohort. 
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Figure 2   Heatmap showing the probability of gastro-intestinal (GI) cancer in the overall IDA cohort 
(n=2390) according to age, sex, blood haemoglobin concentration (Hb: g/l) and mean cell volume 
(MCV: fl). The darker the box, the higher the GI cancer risk – as shown on the risk key. The risk ranges 
are based on positive predictive value quartiles, with the lowest quartile divided in two 
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FIT pilot study 
A total of 62 subjects at predicted high risk of GI malignancy returned an adequate faecal sample for 
FIT analysis and completed their scheduled investigations. Of these 17 (27.4%) proved on subsequent 
investigation to have a GI cancer (upper GI - 2, right colon - 14, left colon - 1). A summary of the 
results is shown in Table 2 - FIT positivity was associated with GI malignancy (OR = 6.6, 95% CI 1.6 - 
51.8), and this significant association persisted after adjustment for the IDIOM score variables of age, 
sex, Hb and MCV. However, the sensitivity of FIT for GI cancer was low at 23.5% (95% CI 6.8 – 49.9%), 
and this only increased to 26.7% (95% CI 7.8 – 55.1%) with exclusion of the upper GI cancers. 
 
 
Table 2 Distribution of gastro-intestinal (GI) cancers by faecal immunochemical testing (FIT) result in 
62 subjects with IDA at predicted high risk 
 
         
  
  GI cancer 
  Negative (n=45) Positive (n=17) 
FIT result 
Negative (n=56) 43 13 
Positive (n=6) 2 4 
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App development 
An App (Predict GI Cancer in IDA) was developed based on the model. This generates an estimate of 
GI cancer risk (with 95% confidence interval) following the insertion of data for the four key variables 
– age, sex, Hb and MCV. The whole process takes just a few seconds, which lends itself to use in busy 
clinical settings, and our intention is to make the App freely available following MHRA approval and 
CE marking. A screenshot from the App is shown in Figure 3. 
 
Figure 3 A screenshot from the App Predict GI Cancer in IDA 
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Discussion 
IDA is a problem commonly encountered in clinical practice, and the prevalence of underlying GI 
cancer in IDA is the primary justification for urgent investigation 3-8. Bidirectional endoscopy (BDE), 
combining gastroscopy and colonoscopy in the same session, is generally accepted as the most 
efficient method of assessing the GI tract unless there are clear clinical clues as to the cause 7. It does 
however carry a small but significant risk of complications, particularly in the elderly and those with 
major co-morbidities, and it is important to consider the risk-benefit ratio for the investigation of IDA 
on an individual case basis. 
BDE is also labour-intensive, taking up to an hour to complete for each patient - yet over 90% of 
procedures for IDA will not reveal malignancy. Because it is common, IDA is a major drain on 
investigational resources, accounting for a substantial proportion of the workload in many Endoscopy 
units - with estimates in the region of 20% of all diagnostic examinations 2. Any manoeuvre to safely 
reduce the number of necessary investigations has the potential to make a substantial positive 
impact on both costs and waiting times. 
There is therefore the need for a simple and reliable pre-test predictor of the risk of underlying 
malignancy that is sufficiently discriminating to be clinically useful for patient-centred counselling. 
Effective risk stratification is a potentially useful clinical tool for two reasons. Firstly, it allows the 
identification of a high-risk sub-group who warrant accelerated investigation and can be advised 
accordingly. Secondly it reveals individuals at very low risk who are unlikely to benefit from invasive 
investigation and may wish to make a considered decision not to proceed. The development of an 
App means that GI cancer risk can be computed in a few seconds, with obvious benefit in busy clinical 
settings. 
The findings of this study have limitations. Firstly, the predicted GI cancer risk is in all cases greater 
than 0% and less than 50%. Secondly, whilst GI cancer is the most important cause of IDA, it is not 
the only one – and we know from previous work that the model is not useful in predicting the 
likelihood of these other causes 10. For these two reasons, the model can never be more than a guide 
to the need for invasive investigation. Finally, whilst large the study is based on a single centre 
experience, raising the question of universal applicability. Work is underway to address this by 
validating the model on a totally independent external IDA dataset. 
The study reported here builds on previous reports from our group and others 9 10 by confirming in a 
much larger IDA cohort that age, sex and Hb are all strong independent predictors of the risk of GI 
cancer. It also reveals a relationship with MCV, albeit less strong – barring a single report on a very 
small cohort 21 this has not been evident in previous analyses 9 10, and has perhaps emerged in this 
study because of the substantially larger cohort size. The observations are further strengthened by 
the findings of the internal prospective validation exercise reported here.  
The predictive value of age and sex is not unexpected, given that the incidence of the major GI 
malignancies rises steeply after the age of 70 years, particularly in males 22 23. It may be that Hb is 
predictive of GI cancer risk simply because the nature of the pathology means that GI malignancy is 
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disproportionately more likely than the other (non-malignant) causes of IDA to lead to greater 
degrees of anaemia.  
The explanation for the effect of MCV on risk is less clear. It might perhaps reflect either chronicity 
or severity of the depletion of body iron stores in those with underlying GI cancer. Although the 
analysis of iron studies does not support the latter explanation, ferritin and transferrin saturation are 
surrogate markers of iron stores and may be influenced by other factors. Serum ferritin in particular 
is an acute phase protein, and may therefore be spuriously high in individuals with malignancy.  
IDA is a particular challenge in the elderly 24, as this is the age-group with the highest prevalence of 
IDA, and the highest risk of underlying GI cancer 2. But it is also the age-group at highest risk of 
complications from invasive investigation or from subsequent surgery if required – and debatably the 
least to gain from intervention. Management planning in this situation needs to be made on a case-
by-case basis, and whilst only one element of the risk-benefit equation, an accurate prediction of GI 
cancer risk can only help the individual concerned to reach the right decision.  
One of the striking findings of the study is the identification of sub-groups with a very low GI cancer 
risk. Indeed, in the 10% of the total cohort with a predicted risk of less than 1.5%, no GI cancers were 
found. It is important to note that this includes some post-menopausal females, as shown in Figure 
2. The finding is unlikely to be the result of referral bias, as younger women with mild anaemia are 
the IDA sub-group least likely to be referred unless there was some other reason for suspecting GI 
disease, for example a strong family history of GI cancer.  
It is important to stress that “low-risk” does not equate to “no risk”, and that additional fail-safes 
need to be incorporated before advocating a no investigation policy for low risk subgroups, a process 
known as diagnostic safety-netting 25. The first safety-net for “low risk” IDA is ensuring a full and 
sustained haematological response to a course of iron replacement therapy. This should already be 
standard practice, and has been shown to predict a very low risk of missed pathology following BDE 
in those with IDA 26. 
A second potential safety-net is testing for tiny quantities of blood in a faecal sample using FIT. The 
development of FIT is undoubtedly a major step forward in the risk assessment of patients in primary 
care presenting with lower GI symptoms, and in screening programmes for colorectal cancer (CRC) 
such as the NHS England Bowel Cancer Screening Programme 27-30. It has a greater sensitivity for CRC  
(the commonest GI cancer underlying IDA) than guiac-based testing for faecal occult blood 31 32, and 
has been shown to be of some predictive value for GI cancer in the IDA population without clinical 
risk scoring 27 33 34. The situation might be analogous to established practice in the diagnosis of 
pulmonary embolism, where it is accepted that those with a low clinical probability score and a low 
test result (for d-dimer) have such a vanishingly low risk that further investigation is not warranted 
35.  
The pilot study reported here demonstrates that in a high-risk IDA sub-group FIT can predict the 
presence of CRC, but the sensitivity of 26.7% is disappointingly low. Numbers are obviously small, but 
this suggests that FIT may not be a particularly helpful adjunct to the IDIOM score in predicting GI 
cancer risk, at least at the 50 μg Hb/g faeces detection threshold. It may be that FIT at a lower 
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detection threshold might improve the sensitivity for CRC in IDA without an unacceptable fall in 
specificity, although a recent meta-analysis demonstrates only a marginal improvement in sensitivity 
on reducing the FIT threshold from ≥30 to 10 μg Hb/g faeces, despite more than doubling the number 
of positive results 36. 
The low sensitivity found here may at first sight seem surprising, but it is important to bear in mind 
that whilst right-sided lesions account for about 35% of all CRCs, the figure is over 80% for the sub-
group presenting with IDA 2. Concerns have been raised about the sensitivity of FIT for right-sided 
CRC 33, and two recent real-world studies have confirmed that this is an issue, reporting that about 
10% of all CRCs had a FIT of less than 10 μg Hb/g faeces, most of these being right-sided tumours 
presenting with IDA 28 29. An analysis of quantitative FIT results revealed median concentrations of 
41.6 and 286.8 μg Hb/g faeces for right-sided (n=17) and left-sided (n=23) CRCs respectively (P < 0.03) 
29.  
A recent systematic review of CRC detection by FIT in IDA cohorts yielded 5 studies with a sensitivity 
of 0.82 (95% CI 0.68–0.90), though most were small, and the evidence quality was poor with a high 
risk of bias 27. Further research in this area is warranted, but the provisional conclusion must be that 
a negative FIT does not reliably exclude CRC in the context of IDA. Following on from this, it may be 
safest to regard IDA and FIT as complementary indicators of the possibility of underlying CRC.  
In conclusion this study has extended previous observations, confirming that the simple and objective 
criteria of age, sex and Hb are strong and independent predictors of the risk of underlying GI cancer 
in subjects with IDA, and the additional benefit of incorporating MCV into the risk stratification 
model. It has demonstrated that in combination these variables can identify 10% of the study 
population who are at ultra-low risk. The development of an App based on this model adds practical 
value in a clinical setting.  
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